- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Single-subject research.
Displaying page 1 of 1.
EudraCT Number: 2013-004244-37 | Sponsor Protocol Number: 13HH1824 | Start Date*: 2014-02-21 | |||||||||||
Sponsor Name:Imperial College London | Imperial College NHS Healthcare Trust | |||||||||||||
Full Title: The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition | |||||||||||||
Medical condition: Traumatic Brain Injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002719-23 | Sponsor Protocol Number: BT8009-100 | Start Date*: 2020-10-29 | |||||||||||
Sponsor Name:BicycleTx Ltd. | |||||||||||||
Full Title: BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies | |||||||||||||
Medical condition: Nectin-4 Expressing Advanced Malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006597-23 | Sponsor Protocol Number: UX143-CL301 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta. | |||||||||||||
Medical condition: Osteogenesis imperfecta (OI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Prematurely Ended) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003951-23 | Sponsor Protocol Number: AG-221-AML-005 | Start Date*: 2016-07-08 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 P... | |||||||||||||
Medical condition: Newly diagnosed acute myeloid leukemia (AML) habouring an isocitrate dehydrogenase 1 (IDH1) or an isocitrate dehydrogenase 2 (IDH2) mutation, respectively, who are not candidates to receive intensi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PT (Completed) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
